Comprehensive Study Notes: General Anaesthetics, Alcohols, Sedative-Hypnotics, Antiepileptics, Antiparkinsonian Drugs, Antipsychotics, Antidepressants, Antiarrhythmics, Antihypertensives

General Anaesthetics (Chapter 27)

• Definition and goals
  • General anaesthetics (GAs) produce reversible loss of all sensation and consciousness.
  • Cardinal features: loss of all sensation (especially pain), sleep/unconsciousness with amnesia, immobility with muscle relaxation, abolition of somatic and autonomic reflexes.
  • Modern practice: balanced anaesthesia using a combination of inhaled and IV drugs, each for a specific purpose.
• History
  • Pre-19th century pain-obtuning methods: alcohol, opium, cannabis, concussion, asphyxia.
  • 1844: Horace Wells (nitrous oxide) demonstration; pain relief inconsistent.
  • 1846: Morton demonstrates ether anaesthesia; rapid adoption.
  • 1847: Chloroform used by James Young Simpson; popular despite toxicity.
  • 1929: Cyclopropane; 1956: halothane heralded; 1935: first IV anaesthetic thiopentone.
• Mechanism of general anaesthesia: evolving view
  • Action not via a single universal mechanism; now agent-specific theory prevails.
  • Lipid/water partitioning and MAC historically linked to potency (Mayer & Overton, 1901): potency correlates with lipid solubility.
  • Minimal Alveolar Concentration (MAC): the lowest alveolar concentration needed to produce immobility in 50% of individuals in response to a painful stimulus.
  • MAC is a valid potency index for inhalational GAs and remains fairly constant in young adults; MAC declines with age (beyond ~50 years).
  • Correlation: MAC correlates with oil:gas partition coefficient (lipophilicity) but that reflects CNS entry, not mechanism.
  • Unitary hypothesis replaced by agent-specific mechanism; evidence supports direct interactions with hydrophobic domains of membrane proteins or lipid–protein interfaces.
  • Targets: ligand-gated ion channels (not voltage-gated), notably GABAA receptor Cl− channels; activation of GABAA Cl− channels by many GAs, barbiturates, benzodiazepines, and propofol.
  • Other actions: N2O and ketamine inhibit NMDA receptors (excitatory); two-pore-domain K+ channels implicated in GA-induced hyperpolarization; interactions with synaptic proteins and discrete loci in cerebrospinal axis.
  • Unconsciousness likely linked to thalamus/reticular activating system; amnesia to cortex/hippocampus; immobility to spinal cord.
• Pharmacokinetics of inhalational anaesthetics
  • Inhaled anaesthetics diffuse rapidly via alveoli; depth determined by potency (MAC) and brain partial pressure; induction/recovery depend on brain PP changes.
  • Key determinants of brain PP:
    1) Inspired partial pressure (inspired gas tension)
    2) Pulmonary ventilation (minute ventilation)
    3) Alveolar exchange and perfusion (ventilation–perfusion mismatch)
    4) Blood:gas partition coefficient (λ) — solubility in blood; higher solubility → slower induction/recovery (e.g., ether is highly soluble; N2O is poorly soluble)
    5) Tissue solubility; adipose storage: more lipid-soluble agents accumulate in fat; slower washout (halothane, isoflurane, desflurane vary).
    6) Cerebral blood flow; CO2-induced vasodilatation speeds induction/recovery; CO2 also stimulates respiration, aiding transport.
  • Elimination: lungs are primary route; metabolism significant mainly for halothane (≈20% hepatic metabolism); N2O largely unmetabolized; diffusion gradients reversed at discontinuation, causing washout.
• Two important concepts in inhalational anaesthetics
  • Second gas effect: when a high BV inhaled gas (e.g., N2O at 70–80%) is used with another GA, induction of the second agent accelerates due to increased alveolar uptake; reverse occurs on discontinuation (diffusion hypoxia) if 100% O2 is not given briefly after stopping N2O.
  • Diffusion hypoxia: after N2O cessation, rapid diffusion of N2O into alveoli dilutes O2; prevented by continuing 100% O2 for several minutes post-discontinuation.
• Techniques of inhalation anaesthesia 1) Open drop method: liquid poured over mask; high vapor loss; simple; mainly cheap anaesthetics. 2) Machine-based delivery (gas cylinders, vaporizers, flow meters, etc.)
  • Open system: no rebreathing; high flow; accurate O2/GA concentrations; more drug use.
  • Closed system: rebreathing through soda lime; low flow; economical; suitable for expensive agents; less air contamination; difficult to exact control.
  • Semiclosed system: partial rebreathing; intermediate flow.
• Ideal properties of an inhalational anaesthetic (summary)
  • For patient: pleasant, nonirritant, minimal nausea, fast induction/recovery, no after-effects.
  • For surgeon: adequate analgesia, immobility, muscle relaxation; nonflammable and nonexplosive (compatibility with cautery).
  • For anaesthetist: easy, controllable, versatile; wide margin of safety (BP stability); minimal organ toxicity; potent at low concentrations; rapid depth adjustments; stable and storeable; nonreactive with equipment.
• Inhalational anaesthetics (classification and properties) -- Table 27.1 snapshot
  • Ether: highly volatile liquid; pungent; MAC high; slow induction/recovery; potent analgesia; augmented reflex sympathetic activity; explosive; now rarely used in developed areas; still used in some developing regions due to cost and open-drop feasibility.
  • Halothane: volatile liquid; non-irritant; moderate MAC; intermediate blood solubility; myocardium depression; hepatic risk (rare hepatitis); uterine/intestinal relaxation; good for asthmatics; can cause BP drop.
  • Isoflurane: widely used; rapid induction/recovery; less cardiac sensitization; minor pungency; low metabolism; good neurosurgery profile.
  • Desflurane: very rapid induction/recovery; very low blood solubility; rapid titration; irritant; not ideal for induction.
  • Sevoflurane: rapid induction/recovery; non-irritant; friendly for pediatric use; higher cost; reacts with soda lime; metabolized ~3%; renal concerns minimal.
  • Nitrous oxide (N2O): colorless gas; low potency; MAC ≈ 105% (cannot produce surgical anaesthesia at 1 atm alone); analgesic at subanesthetic concentrations; second gas effect; diffusion hypoxia; increases cerebral blood flow; carrier/adjunct; not a sole agent for major surgery.
• Intravenous fast-acting drugs (induction) -- list with notes
  • Thiopentone (thiopental): ultrashort-acting barbiturate; induction within ~15–20 s; redistribution to tissues leads to wake in 6–10 min; liver metabolism; poor analgesia; potential for myoclonus; high risk in porphyria; extravasation risk; distribution t1/2 ~3 min; elimination t1/2 ~8–12 h; strong CNS depressant; adverse effects include laryngospasm if light anesthesia; interactions with other CNS depressants; not analgesic.
  • Methohexitone: similar to thiopentone but more potent; faster recovery; rapid hemodynamic effects; more excitability in recovery.
  • Propofol: widely used; 1% propofol emulsion; induction 15–45 s; rapid distribution t1/2 2–4 min; elimination t1/2 ~100 min; minimal airway irritation; excellent for outpatient; low PONV; injection pain common; needs lidocaine coadministration; maintains hemodynamics less with vasodilation; use with fentanyl for total IV anaesthesia; cognitive function recovers quickly; consider sedation in ICU; safety in asthmatics; adverse effects include hypotension, respiratory depression. Maintenance via infusion (2 mg/kg for induction; 100–200 μg/kg/min for maintenance).
  • Etomidate: induction agent; stable hemodynamics; minimal CV depression; myoclonus and injection pain; poor analgesia; good for septic or unstable patients; short action.
  • Dissociative anaesthesia (Ketamine): dissociative state; preserved respiration; bronchodilation; sympathetic stimulation; potential for emergence delirium; good in hypovolemia; contraindicated in coronary artery disease or raised ICP; used for short procedures in specific contexts.
  • Dissociative analgesia opioids: Fentanyl; morphine; sufentanil/alfentanil; used as adjunct to inhaled or IV anaesthetics; fentanyl potent, rapid onset, short duration; anesthesia maintenance via infusion; narcotic analgesia; monitor respiratory depression; interactions with other CNS depressants; sedation; risk of awareness under light anesthesia if not combined.
  • Dexmedetomidine: alpha-2 agonist; sedation with minimal respiratory depression; analgesia; used in ICU sedation; hypotension/ bradycardia risk; limited CNS depression compared to other agents.
• Conscious sedation and preanaesthetic medication
  • Conscious sedation is a monitored state of altered consciousness with local/regional anesthesia; patient remains responsive and airway protective reflexes intact; used for diagnostic/short procedures in apprehensive or compromised patients.
  • Agents used include: benzodiazepines (diazepam, lorazepam, midazolam), propofol, nitrous oxide, fentanyl; sometimes opioids with benzodiazepines.
• Complications and interactions
  • Intraoperative and postoperative: respiratory depression, hypotension, arrhythmias, airway threats (laryngospasm), emergence delirium, postoperative nausea/vomiting, cognitive changes in elderly, etc.
  • Interactions with other CNS depressants, antihistamines, clonidine, MAO inhibitors; specific interactions with halothane (arrhythmias) and with drugs affecting GABA or NMDA systems.
  • Rack risk of malignant hyperthermia with some agents (esp. halogenated inhaled anesthetics) – treat with dantrolene.
• Premedication and preoperative medications
  • Aims: reduce anxiety, amnesia, analgesia, reduce secretions and vagal stimulation, antiemetic effects, gastric protection.
  • Agents used include sedatives (benzodiazepines like diazepam/lorazepam; midazolam), opioids (morphine, pethidine), anticholinergics (atropine, hyoscine, glycopyrrolate), neuroleptics (chlorpromazine, haloperidol), H2 blockers or PPIs, antiemetics (metoclopramide, ondansetron), and others (promethazine) depending on patient.
• Problem-directed studies (exemplars)
  • GA-related questions: MAC relationship; second gas effect; diffusion hypoxia; airway reflexes; Malignant hyperthermia; drug interactions; choice of induction agents; premedication regimens.

Ethyl and Methyl Alcohols (Chapter 28)

• Ethanol (ethyl alcohol)
  • Pharmacology: a CNS depressant with dose-dependent effects; CNS depression, sedation, anxiolysis, disinhibition, impaired coordination, reduced reflexes; high doses cause anesthesia and coma; respiration and CV effects depend on dose; chronic alcohol can cause hepatic steatosis, cirrhosis, cardiomyopathy, neuropathy, Wernicke–Korsakoff syndrome, malnutrition.
  • Absorption & kinetics: absorbed from stomach and especially small intestine; zero-order kinetics at high intake; distribution volume ~0.7 L/kg; crosses BBB and placenta; hepatic oxidation mainly via ADH and CYP2E1; zero-order kinetics means the rate of metabolism is constant irrespective of concentration; excretion via lungs (breath-testing) and kidneys; alcohol dehydrogenase converts to acetaldehyde; acetaldehyde further oxidized to acetate by aldehyde dehydrogenase.
  • Metabolism: ethanol → acetaldehyde → acetate; in chronic alcoholics CYP2E1 induction increases metabolism; acetaldehyde is toxic and contributes to aversive symptoms; acetaldehyde associated with disulfiram-like reactions when alcohol is consumed with certain drugs.
  • Clinical effects by plasma levels: mild intoxication (30–60 mg/dL) with euphoria and reduced inhibition; 80–150 mg/dL confusion, ataxia; 150–200 mg/dL slurred speech; >200 mg/dL stupor; >300 mg/dL coma; chronic use associated with tolerance and dependence. Increases HDL and reduces LDL oxidation; small protective cardiovascular effects in moderate drinkers; risk of hypertension and cardiomyopathy with chronic exposure.
  • Mechanisms: increases GABAergic neurotransmission; inhibits NMDA receptors; enhances dopamine release in reward circuits; alters synaptic signaling; affects enzymes like Na+/K+ ATPase.
• Alcohol poisoning and treatment (methanol/ethylene glycol covered in later sections)
  • Methanol and ethylene glycol poisoning: rare but potentially lethal; treatment includes fomepizole (ADH inhibitor), ethanol therapy to saturate ADH and slow methanol/ethylene glycol metabolism; fomepizole preferred due to better safety; in severe cases, hemodialysis; supportive care; treat acidosis with bicarbonate; folate supplementation; reverse retinal damage from formic acid (methanol).
• Uses and adverse effects
  • Clinical uses include external antiseptic, antisecretory, appetite stimulant, and to aid gastric mucosa protection; formal contraindications include pregnancy; interactions with other CNS depressants; social and behavioral effects; intoxication risk with driving or dangerous activities.
• Methyl alcohol (methanol) – important toxicology
  • Metabolized to formic acid; formic acid is highly toxic causing metabolic acidosis and optic neuropathy; lethal doses vary; fomepizole or ethanol as antidotes; fomepizole preferred for methanol poisoning; use of folate cofactors to enhance metabolism of formate; dialysis for severe cases.
• Ethylene glycol poisoning
  • Toxic metabolites cause metabolic acidosis and nephrotoxicity; fomepizole recommended; ethanol as alternative; dialysis for severe cases.
• Problem-directed studies (examples)
  • Alcohol interactions; effects of chronic misuse; methanol/ethylene glycol poisoning management; guidelines for safe drinking: 1–2 drinks/day as a general limit; differences in risk between men and women; the disulfiram reaction; alcohol abstinence in categories with risk.

Sedative-Hypnotics (Chapter 29)

• Definitions and spectrum
  • Sedative: decreases anxiety and arousal, not necessarily sleep; Hypnotic: induces sleep; both are CNS depressants with varying onset/duration; barbiturates historically dominated but now largely replaced by benzodiazepines (BZDs) and newer non-BZD hypnotics because of safety and tolerability.
• Sleep architecture and effects
  • Sleep stages 0–4 and REM; sedatives/hypnotics alter sleep stage distribution; e.g., barbiturates reduce REM, suppress stage 3/4; rechallenge with daily use leads to tolerance and rebound insomnia on cessation. Z-drugs (zaleplon, zolpidem, zaleplon) target α1-containing GABAA receptors with less disruption of sleep architecture; ramelteon (melatonin receptor agonist) and melatonin have roles as sleep onset aids.
• Barbiturates (long-, short-, ultra-short acting)
  • Act via GABAA receptor; potent CNS depressants with significant adverse effects including respiratory depression; tolerance/dependence; strong sedation and cognitive impairment; significant drug interactions via hepatic enzyme induction; withdrawal risk; not first-line for insomnia due to safety concerns.
• Benzodiazepines (BZDs)
  • Mechanism: allosteric modulators of GABAA receptor increasing Cl− influx and GABAergic inhibition; subtypes of GABA receptor isoforms (α1, α2, α3, α5) contribute to sedation, anxiolysis, muscle relaxation, anticonvulsant effects; BZDs have wide variance in pharmacokinetics (lipophilicity, half-life, active metabolites) leading to different clinical uses: long-acting (diazepam, flurazepam), intermediate (temazepam), short-acting (triazolam); recent non-BZD hypnotics (z-drugs) with α1 selectivity produce hypnotic effects with less anxiolysis and minimal anticonvulsant effects.
  • Pros: rapid onset, reliable hypnotic effect with lower risk of respiratory depression than barbiturates; reversal available with flumazenil.
  • Cons: withdrawal risk, cognitive impairment, anterograde amnesia, potential for dependence; sleep architecture alteration varies by agent; elderly more susceptible to side effects; potential interactions with alcohol and other CNS depressants.
• Non-benzodiazepine hypnotics (z-drugs)
  • Zolpidem (short acting), Zaleplon (ultra-short acting), Eszopiclone (slightly longer acting) have high affinity for α1-containing BZD receptor; improved safety profile with less withdrawal and rebound insomnia; minimal impact on sleep stages, but some morning sedation possible; no anti-anxiety or anticonvulsant properties; potential for dependence albeit lower; half-lives and dosing vary.
• Novel agents
  • Melatonin receptor agonists: ramelteon; melatonin receptor agonists; minimal next-day sedation; potential for jet-lag; safety data emerging.
  • Flumazenil: competitive benzodiazepine antagonist; reverses BZD effects in overdose or overdose with sedation; used in BZD overdose and post-anesthetic reversal; limited efficacy in mixed CNS depressant poisoning.
• Conscious sedation and premedication (briefly)
  • Conscious sedation uses benzodiazepines (diazepam, midazolam) with analgesics, local anesthesia or regional blocks; aims to maintain airway function; consider safety and dosing to minimize oversedation and ensure rapid recovery.
• Complications and adverse effects
  • Drowsiness, cognitive impairment, ataxia; anterograde amnesia; respiratory depression with hypnotic doses (less with BZDs than barbiturates); rebound insomnia and withdrawal symptoms; paradoxical reactions (rare); interactions with alcohol and CNS depressants; in elderly, delirium and confusion are more common.
• Problem-directed studies (example)
  • A question about selecting hypnotics for occasional insomnia; considerations of withdrawal, next-day impairment, and safety in elderly.

Antiepileptic Drugs (Chapter 30)

• Overview and classification
  • Antiepileptic drugs (AEDs) suppress seizures but do not cure epilepsy; categories include barbiturates, hydantoins, iminostilbenes, succinimides, valproates (carboxylic acids), benzodiazepines, GABA analogues, and newer agents.
  • Decision framework: seizure type (generalized, focal), patient-specific factors (pregnancy, comorbidities, interactions), and monotherapy vs add-on therapy.
• Major classic AEDs (mechanisms, uses, and key points)
  • Phenobarbitone (barbiturate): broad antiseizure action; high sedation and cognitive effects; strong enzyme induction; long half-lives; susceptibility to porphyria in some individuals; adjunct to other AEDs; adverse effects include cognitive impairment, drowsiness, rash, porphyria risk.
  • Phenytoin (diphenylhydantoin): stabilizes neuronal membranes by prolonging the inactivated state of voltage-gated Na+ channels; efficacy in GTCS and SPS; can reduce PTZ seizures; metabolic clearance is capacity-limited; potential for multiple drug interactions; gingival hyperplasia, hirsutism, megaloblastic anemia; teratogenic risk (foetal hydantoin syndrome).
  • Carbamazepine: Na+ channel blocker with actions similar to phenytoin but pharmacodynamics differ; effective for partial seizures and trigeminal neuralgia; autoinduction of metabolism; potential for hyponatremia; hepatic enzyme induction; interactions with several drugs; pregnancy risks.
  • Oxcarbazepine: newer congener with fewer epoxide-related toxicities; less autoinduction; hyponatremia risk; indications similar to carbamazepine.
  • Ethosuximide: selective for absence seizures; acts on thalamic T-type Ca2+ channels; no effect on GTCS; relatively well tolerated; some GI side effects.
  • Valproic acid (valproate): broad-spectrum; inhibits Na+ channels, enhances GABA, weak T-type Ca2+ current reduction; effective for absence, GTCS, SPS; risk of hepatotoxicity and teratogenicity; monitoring for liver function; interactions with other AEDs;
  • Lamotrigine: broad-spectrum; prolongs Na+ channel inactivation; less sedation; risk of rash (including Stevens–Johnson); interactions with valproate; useful in refractory partial seizures and some generalized epilepsies; weight neutral to modestly weight gain.
  • Gabapentin and Pregabalin: GABA analogues; modulate Ca2+ channels with α2δ subunit; add-on therapy for partial seizures; analgesic effects in neuropathic pain; relatively well tolerated; minimal drug interactions.
  • Topiramate: multiple mechanisms including Na+ channel block, GABA enhancement, glutamate receptor antagonism; effective for partial and GTCS; cognitive side effects and weight loss; also approved for migraine prophylaxis.
  • Levetiracetam: novel; binds SV2A; broad-spectrum add-on therapy for refractory partial seizures; low drug interactions; generally well tolerated but can cause somnolence and mood changes.
  • Tiagabine: GABA reuptake inhibitor; increases GABA in synapse; add-on therapy in partial seizures; sedation and cognitive effects possible.
  • Vigabatrin: GABA transaminase inhibitor; potent for refractory seizures; risk of irreversible visual field loss; limited use.
  • Lacosamide: enhances Na+ channel inactivation; add-on therapy for partial seizures; generally well tolerated; IV forms exist.
• Special topics
  • Monitoring and pharmacokinetics: many older AEDs show non-linear kinetics; autoinduction (carbamazepine, phenytoin) affects dose and response; therapeutic drug monitoring valuable for some drugs (e.g., phenytoin, valproate).
  • Pregnancy and teratogenic risk: valproate and some AEDs increase fetal risk; folic acid supplementation; dose adjustments may be necessary.
  • Drug interactions: AEDs influence hepatic enzymes (CYPs); polytherapy considerations; enzyme induction vs inhibition; interactions with barbiturates, haloperidol, etc.
• Problem-directed studies (examples)
  • Case-based questions on switching/add-on strategies, management of status epilepticus, or optimizing seizure control with minimal side effects; monitoring the serum levels and managing teratogenic risks.

Antiparkinsonian Drugs (Chapter 31)

• Pathophysiology of Parkinson’s disease (PD)
  • Degeneration of nigrostriatal dopamine (DA) neurons in the substantia nigra pars compacta reduces DA in the striatum; imbalance with acetylcholine (ACh) leads to motor symptoms: rigidity, tremor, bradykinesia.
  • DA receptor subtypes: D1-like (D1, D5) and D2-like (D2, D3, D4); D1/D2 receptor activity balance motor output via direct and indirect pathways in the basal ganglia.
• Levodopa – the mainstay
  • Levodopa (L-dopa) is the DA precursor that crosses the blood–brain barrier; peripherally decarboxylated to DA; brain DA improves motor symptoms, particularly bradykinesia and rigidity; does not reverse neuronal loss; long-term use associated with fluctuations (wearing-off) and dyskinesias.
  • Peripheral decarboxylase inhibitors (carbidopa, benserazide) block peripheral DA formation, increasing central availability and reducing peripheral side effects (nausea, vomiting); combinations termed Co-careldopa (carbidopa+levodopa).
  • Pharmacokinetics: rapid absorption; many tissues convert much of the dose; only ~1–2% crosses BBB; plasma t1/2 ~1–2 h; interactions with pyridoxine (vitamin B6) reduces peripheral conversion; central DA repletion improves motor function but may cause psychiatric effects and dyskinesias.
  • Adverse effects: nausea, orthostatic hypotension, dyskinesias, hypotension, sedation, psychosis; impulse control disorders; complications include fluctuations in motor performance (on-off), wearing off; long-term use associated with dyskinesias.
• Dopamine receptor agonists
  • Bromocriptine (ergot-derived; D2 agonist with some D1 activity)
  • Pramipexole and Ropinirole (non-ergot, preferential D2/D3 agonists)
  • Use: as monotherapy in early PD or as adjunct to L-dopa in later PD to smoothen motor fluctuations and possibly slow neurodegeneration; can delay the need for L-dopa; side effects include nausea, somnolence, orthostatic hypotension, impulse control issues; less dyskinesia than L-dopa in some settings.
• MAO-B inhibitors
  • Selegiline, Rasagiline: prolong DA action by inhibiting DA breakdown; useful as adjunct to L-dopa; potential neuroprotection hypotheses; adverse effects include insomnia, confusion; interactions with serotonergic drugs (serotonin syndrome risk when combined with SSRIs or TCAs).
• COMT inhibitors
  • Entacapone, Tolcapone: block peripheral levodopa metabolism, increasing central availability; entacapone is peripheral and relatively safe (hepatotoxicity risk lower than tolcapone); tolcapone has hepatotoxicity caveats; used to smooth wearing-off by prolonging levodopa half-life.
• Other agents
  • Amantadine: NMDA receptor antagonist; increases DA release; may reduce dyskinesias; modest benefit.
  • Anticholinergics: help with tremor predominance; limited utility in older patients due to cognitive adverse effects.
• Nonpharmacological and management considerations
  • Therapy tailored to stage; early disease may benefit from DA agonists or MAO-B inhibitors to delay L-dopa; as disease progresses, levodopa remains the most effective drug but with dose fluctuations.
• Problem-directed studies (examples)
  • Scenarios involving management adjustments in PD with motor fluctuations; considerations of combination therapies; monitoring adverse effects and dyskinesias; decisions about when to initiate L-dopa and how to combine with other agents.

Antipsychotic Drugs and Antimanic Drugs (Chapters 32–33)

• Antipsychotics (Neuroleptics)
  • Classical/typical antipsychotics (e.g., chlorpromazine, haloperidol, fluphenazine, trifluoperazine, thioridazine) are potent D2 receptor antagonists; provide relief of positive symptoms (delusions, hallucinations, agitation) but have extrapyramidal side effects (EPS) including parkinsonism, dystonia, akathisia, tardive dyskinesia.
  • Atypical (second-generation) antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, others) have lower EPS risk and more favorable metabolic profiles; clozapine is effective in treatment-resistant schizophrenia but carries risk of agranulocytosis; others may cause weight gain, dyslipidemia, and glucose intolerance.
• Mechanisms and receptor pharmacology
  • DA antagonism in mesolimbic pathways reduces positive symptoms, but blockade in nigrostriatal pathways leads to EPS; atypical antipsychotics often target 5-HT2A receptors in addition to D2 blockade, improving negative symptoms with fewer EPS.
• Antidepressants and anxiolytics (Ch 33)
  • TCAs (imipramine, amitriptyline, clomipramine) block reuptake of NA and 5-HT but have anticholinergic and cardiotoxic risks; SSRIs (fluoxetine, sertraline, citalopram, paroxetine, escitalopram) have more favorable safety profiles; SNRIs (venlafaxine, duloxetine) block serotonin and norepinephrine reuptake; atypicals (mirtazapine, trazodone, bupropion) offer varied action profiles; buspirone (Azapirone) for generalized anxiety with fewer sedative effects; benzodiazepines for short-term anxiety relief with dependence risks; flumazenil reverses BZD effects.
• Antimanic drugs (Ch 31) – Lithium and alternatives
  • Lithium carbonate: mood stabilizer; mechanism involves inositol phosphate pathway and reduction of phosphatidylinositol signaling; decreases manic episodes and provides prophylaxis in bipolar disorder; monitoring in therapeutic range; narrow therapeutic window; adverse effects include tremor, polyuria, hypothyroidism, weight gain; interactions with diuretics, NSAIDs, ACE inhibitors; caution in pregnancy.
  • Alternatives: valproate, carbamazepine, lamotrigine, atypical antipsychotics (e.g., olanzapine, risperidone, quetiapine, aripiprazole) for mania and bipolar depression; combination therapies (e.g., valproate + lithium, lithium + atypical antipsychotic) often used; careful monitoring for interactions and adverse effects.

Oxygen, Metabolic and Interventional Contexts

• Interconnected topics across chapters include pharmacokinetics and pharmacodynamics of many CNS-active drugs, interactions with anesthesia, and implications for perioperative care.
• Across chapters, a common thread is balancing efficacy and safety: choosing agents with favorable side-effect profiles, considering comorbidities (e.g., thyroid disease with lithium, diabetes with antipsychotics), and minimizing drug interactions in polypharmacy settings.

Key Formulas and Conceptual Notes (LaTeX)

• Minimal Alveolar Concentration (MAC) definition and potency relation
  • MAC is the lowest concentration in pulmonary alveoli required to produce immobility in 50% of individuals in response to a painful stimulus. The potency of inhalational GAs correlates with MAC and with oil:gas partition coefficients; higher lipid solubility generally means lower MAC (more potent) but this is not the sole determinant of mechanism.
  • Example relation: 1 MAC blocks immobility in 50% of cases; 1.3 MAC immobilizes about 95% of subjects. ext{1 MAC}
    ightarrow 50 ext{% immobile}; \ 1.3\text{ MAC} \approx 95\% immobilized.
• Solubility and uptake
  • Blood:Gas partition coefficient: $\lambda<em>{bg}=\frac{C</em>{blood}}{C_{gas}}$ at equilibrium; a higher value indicates slower induction/recovery due to higher blood solubility.
  • Oil:Gas partition coefficient describes lipid solubility and correlates with CNS penetration; agents with high oil:gas partition coefficients tend to be more potent with slower elimination.
• Lipid partitioning and membrane interactions
  • The lipid/water partition concept links potency to partitioning into membranes, supporting a membrane-interaction mechanism for some GAs; however, modern consensus emphasizes agent-specific molecular interactions (e.g., with GABAA receptor sites).
• Basic physics of the circulatory impact of anaesthetics
  • Wall tension in the ventricle (Laplace’s law): $T = P imes r$ where P is intraventricular pressure, r is ventricular radius; decreased radius (through better emptying, or decreased preload) reduces wall tension and myocardial oxygen demand.
• Renin–Angiotensin System (for Chapter 36) – schematic
  • Key relationships (qualitative): Angiotensinogen + renin → Angiotensin I (Ang I) → Angiotensin II (Ang II) via ACE; Ang II acts on AT1 and AT2 receptors; ARBs block AT1 receptors; ACE inhibitors block formation of Ang II and increase bradykinin (cough side effects); direct renin inhibitors (aliskiren) block the rate-limiting step. Important interactions include effects on aldosterone, renal perfusion, and cardiovascular remodeling.

Connections and Real-World Relevance

• General anaesthetics underpin modern surgical practice; balanced anaesthesia minimizes each drug’s adverse effects by targeting specific components of the anaesthetic state ( analgesia, amnesia, immobility, reflex suppression) with combinations of inhalational and intravenous agents.
• The lipid solubility concept (MAC and partition coefficients) helped explain potency of inhalation anaesthetics historically, but agent-specific actions (GABAergic, NMDA, K+ channels) provide a more precise mechanistic framework.
• Alcohol’s complex CNS actions show how a single substance can have multiple, context-dependent neurochemical targets (GABA, NMDA, DA, opioid systems) and how metabolism (zero-order kinetics) influences intoxication and toxicity.
• Antidepressants, antipsychotics, and mood stabilizers interact through monoaminergic signaling and receptor profiles; care is required in polypharmacy contexts due to interactions (CYP enzymes, receptor cross-talk).
• Antihypertensive and antianginal drugs illustrate how cardiovascular therapy integrates hemodynamic principles (preload/afterload, BP, HR), neurohumoral systems (RAAS, sympathetic tone), and tissue-level effects (endothelial function, remodeling). This includes recognizing when combination therapy provides synergistic benefit or when certain drug classes should be avoided in certain comorbid states.

Important Definitions and Concepts (summary)

• MAC: Minimal Alveolar Concentration; potency proxy for inhaled GAs.
• GABAA receptor: major target for many GAs, barbiturates, benzodiazepines, propofol; GABAergic Cl− influx increases neuronal inhibition.
• Second gas effect: augmented uptake of a coadministered GA when a highly soluble gas (e.g., N2O) is used.
• Diffusion hypoxia: decreased alveolar O2 partial pressure after N2O withdrawal; mitigated by 100% O2 briefly after discontinuation.
• Laplace’s law in cardiology: Wall tension = Pressure × Radius; relevant to cardiac workload and the effect of reducing preload on myocardial oxygen demand.
• Zero-order kinetics (ethanol): metabolism proceeds at constant rate independent of concentration, particularly at higher blood levels; affects clinical management of intoxication and poisoning.
• Receptor pharmacology in antipsychotics and antidepressants: D2 receptor blockade; atypicals add 5-HT2A antagonism; risk of EPS vs metabolic syndrome; SSRI/SNRI safety profiles and drug interactions.

Note

• The notes above summarize extensive content across multiple chapters. If you want, I can expand any chapter into an even more detailed, drug-by-drug tabular format (e.g., for Chapter 30, list each AED with mechanism, typical dose range, main indications, key adverse effects, and major interactions) or tailor the notes for a specific exam focus (e.g., clinical case-based questions, pharmacokinetics emphasis, or drug interaction synthesis).